INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
Condition(s) studied
Investigational drug(s) / intervention(s)
Technosphere Insulin: 2 unit
Technosphere Insulin: 4, 8, 12 units
Basal insulin: subcutaneously-injected basal insulin
Study summary
INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 6 to \<18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of an Afrezza plus BI reigmen on participant and parent/legally authorized representative satisfaction. Participants will be followed for 13 weeks during the main phase followed by an optional Extension Phase for participants continuing to use Afrezza in combination with BI for up to 26 weeks.
Eligibility
Primary outcome measure(s)
- Percentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70% — 13 weeks
Percentage of participants with a CGM-measured TIR 70-180 mg/dL ≥70% during 14 days prior to 13-week visit
Trial sites (10)
| Facility | City | Region | Status |
|---|---|---|---|
| Children's Hospital Los Angeles | Los Angeles | California | Recruiting |
| University of California San Francisco | San Francisco | California | Recruiting |
| Barbara Davis Center for Diabetes Young Adult Clinic | Aurora | Colorado | Recruiting |
| Yale University | New Haven | Connecticut | Recruiting |
| University of Florida | Gainsville | Florida | Recruiting |
| Indiana University | Indianapolis | Indiana | Recruiting |
| Joslin Diabetes Center | Boston | Massachusetts | Recruiting |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | Recruiting |
| Baylor College of Medicine | Houston | Texas | Recruiting |
| University of Virginia | Charlottesville | Virginia | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07224321 on ClinicalTrials.gov ↗ ← All trials in the USA